Dopamine Receptor Agonist Combined with Levodopa and Benserazide Hydrochloride Tablets in Patients with Parkinson s Disease
Cardiovascular system symptoms are closely related to the decrease of motor function, quality of life, survival
rate and mortality rate of patients with Parkinson's disease. Therefore, early detection and diagnosis of
cardiovascular function in patients wi th Parkinson's disease is very important. The purpose of this study is to
study the changes of symptoms of patients with Parkinson's disease treated with levodopa and benserazide
hydrochloride tablets and dopamine receptor agonists in order to judge the si tuation of patients with Parkinson's
disease treated, and to explore the difference of clinical manifestations of the long term curative effect and find
a more effective treatment plan. The combination of dopamine receptor agonist and levodopa and benseraz ide
hydrochloride tablets can not only increase the supplement level of dopamine in Parkinson's patients, but also
has the advantages of long acting time and quick acting. It is necessary to let Parkinson's patients take less
levodopa and benserazide hydro chloride tablets to avoid certain side effects and improve the clinical efficacy.
The results of the experimental control group can be seen that the effect of dopamine receptor agonists
combined with levodopa and benserazide hydrochloride tablets on Parkin son's disease patients increased from
60% to 75%.